All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

Add-on Clioquinol in drug-resistant epilepsy: an exploratory study

Living with epilepsy can be challenging, especially when standard anti-seizure medicines fail to keep seizures under control. This trial is investigating whether a medicine called clioquinol can help adults with drug-resistant epilepsy. Participants will take clioquinol alongside their regular epilepsy medicines. The study tests two different amounts: a lower dose for the first two weeks, followed by a higher dose for the next four weeks. Researchers will count how often seizures happen to see if the medicine helps cut them in half. Doctors will also carry out regular health checks and nerve examinations to make sure the medicine is safe and does not cause unwanted side effects. They will also look at how the treatment affects everyday quality of life.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
UZ Leuven
Enrolment target
20
Start
16 Jul 2024

What is this study about?

Epilepsy is a common condition that affects the brain and causes regular seizures. While many people manage their seizures well with standard tablets, around one in three people find that typical medicines do not work well enough. This is often called drug-resistant or refractory epilepsy, and doctors are constantly looking for new treatment options to help.

This early-stage clinical trial is testing a medicine called clioquinol. Clioquinol has been used in medicine before, but researchers now want to explore whether it might also help calm the brain signals that trigger seizures. Because this is an exploratory study, it aims to find out if the drug shows promise and whether it is safe enough for larger studies in the future.

During the trial, clioquinol is given as an 'add-on' treatment. This means you would continue taking your usual epilepsy tablets while adding the study drug. Researchers will track your seizure numbers closely over six weeks to see if there is a meaningful reduction, such as having at least 50% fewer seizures.

Doctors will also monitor your overall wellbeing, checking for any side effects and seeing whether better seizure control helps you feel better in your day-to-day life.

Key takeaways

  • The study tests clioquinol as an add-on treatment for adults with hard-to-treat epilepsy.
  • Participants take a low dose for two weeks, followed by a higher dose for four weeks.
  • The main goal is to see if seizures are reduced by at least 50%.
  • Doctors will carry out regular nerve and blood tests to protect your safety.
  • Taking part is completely voluntary and you can withdraw at any time.

Who may be eligible?

This study is open to adults aged 18 and older who have been diagnosed with drug-resistant epilepsy. This means your seizures continue to happen even though you have already tried standard epilepsy medicines.

Both men and women may be able to take part. Because this is an add-on study, you will likely need to be on a stable dose of your current anti-seizure treatments before starting.

To ensure your safety, the study team will review your full medical history. People with certain other health conditions, specific nerve disorders, or allergies to the study medicine may not be able to join. Your doctor can help determine if this trial suits your personal circumstances.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with epilepsy.
  3. My seizures continue despite trying standard anti-seizure medications.
  4. I am willing to take an extra medicine alongside my usual treatments.
  5. I can attend regular hospital visits and keep an accurate seizure diary.
Answer every question to see your result.

What does participation involve?

If you take part, you will continue with your regular anti-seizure medicines and add clioquinol to your routine. The study lasts for several weeks. You will start on a lower dose of clioquinol for the first two weeks, and if you tolerate it well, you will move to a higher dose for the remaining four weeks.

You will attend clinic appointments (including visits at week two and week six) for regular check-ups. At these visits, doctors will carry out physical checks, blood tests, and special nerve tests to look for any signs of nerve changes (neuropathy). You will also keep a diary to record how many seizures you have and complete questionnaires about your quality of life, daily symptoms, and any side effects.

Potential risks and benefits

The main hope of this study is that clioquinol might reduce the number or severity of your seizures, though there is no guarantee it will help. Like all medicines, clioquinol can cause side effects. In the past, high doses or long-term use have been linked to nerve problems, which is why doctors will check your nerves very closely during the trial. You are free to leave the study at any time without giving a reason, and doing so will not affect your usual NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Belgium

Common questions

Will I have to stop taking my usual epilepsy tablets?

No. Clioquinol is an add-on treatment, meaning you take it in addition to your current prescribed epilepsy medicines.

How long will I be taking the study drug?

The treatment period in this study lasts about six weeks, starting with a lower dose for two weeks before increasing to a higher dose.

What is clioquinol?

Clioquinol is a medicine that has been used in healthcare for many years. Scientists are now exploring whether it can help protect the brain and reduce seizures.

How will the doctors check if it is working?

You will keep a daily seizure diary. The team will compare your diary during the trial with your usual seizure patterns to see if your seizures decrease by half or more.

What happens if I experience side effects?

Doctors will monitor you closely at each visit. If you experience uncomfortable side effects or nerve problems, the team can lower your dose or stop the medicine immediately.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Add-on Clioquinol in drug-resistant epilepsy: an exploratory…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.